Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study systematically reviewed androgenetic alopecia's clinical features, mechanisms, and treatments, highlighting that current drugs have limitations but emerging therapies and personalized treatment strategies could enhance efficacy and outcomes.

This review explores the link between androgenetic alopecia, advanced glycation end products, and RAGE, noting their potential role in exacerbating oxidative stress and inflammation related to hair follicle miniaturization.

This review compiles existing information on the pathogenesis of androgenetic alopecia, highlighting its genetic, hormonal, and environmental factors, but reports no new clinical findings.

This article presents a dissenting opinion, arguing that the case described by Dr. Molina et al. was diffuse alopecia areata, not acute alopecia areata as claimed, emphasizing the importance of distinct clinical differences.

In a mouse model study, researchers developed a methacrylated hyaluronic acid-based hydrogel microneedle patch co-loaded with finasteride and a carbon monoxide-releasing molecule for androgenetic alopecia, which showed better hair regrowth and safety compared to traditional treatments, offering an innovative approach with minimized systemic side effects.

This study highlights that although mogamulizumab is highly effective for treating mycosis fungoides and Sézary syndrome, it frequently causes a variety of rashes as side effects.

This study developed microneedles combining insulin-like growth factor-1 and type XVII collagen, showing more effective hair regeneration and reduced inflammation compared to minoxidil in a mouse model of androgenetic alopecia.

This study found that a topical hair ampoule containing human follicle stem cells significantly improved hair growth and scalp coverage in women with androgenetic alopecia after four months of use.

This study in the United Arab Emirates found that alopecia areata significantly impacts patient quality of life and healthcare resource utilization, particularly among those with higher scalp hair loss.

This study suggests that autologous micrograft technology may be more effective than finasteride in promoting hair growth in patients with androgenetic alopecia.

This study found that patients with androgenetic alopecia showed distinct scalp bacterial imbalances compared to healthy individuals, which were associated with unhealthy lifestyles. These microbial changes might contribute to follicular inflammation, potentially accelerating hair loss in these patients.

This study's review of existing literature suggests potential benefits of red LED photobiomodulation for treating telogen effluvium, but highlights a lack of standardized parameters and calls for further controlled trials.

This review found that alopecia areata significantly impairs quality of life, particularly through embarrassment and self-consciousness, in children and adolescents.

This study found that individuals with androgenetic alopecia had higher scalp microbiome diversity and more complex scalp-gut microbiome networks than those without, suggesting a link between skin-gut microorganisms and hair loss development.

This study describes a multifunctional hydrogel system designed to treat androgenetic alopecia by integrating nanozymes for reactive oxygen species clearance and melanin nano photothermal agents to enhance hair follicle health, suggesting potential for multi-target precision therapy and improved hair growth.

This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

This article reviews the general, pathophysiological, diagnostic, and therapeutic aspects of alopecia frontal fibrosante, highlighting its irreversible nature and the importance of early diagnosis, but it reports no new clinical results.

In this case report, a 23-year-old woman developed localized trichorrhexis nodosa after compulsively applying 3% minoxidil to her scalp for two months.

In this randomized clinical trial, the use of Cellcurin serum for 12 weeks was associated with a significant increase in hair density and terminal hair thickness in individuals with androgenetic alopecia.

In this study, researchers investigated the use of the Pulse Booster Drug Delivery Mesojectgun technology for non-invasive treatment of scalp conditions, finding improvements in hair volume, thickness, and reduction of hair loss in four participants with alopecia after applying specific active ingredients.

In this case report, an 8-year-old girl with burn-induced cicatricial alopecia showed improved graft survival after hair transplantation due to preparatory microfat grafting, which enhanced tissue conditions and possibly increased follicular unit survival rates to about 80%, higher than typically expected.

This study reports that combination therapies, including surgical and various medical treatments, show promise for managing androgenetic alopecia, though further research is necessary to confirm the safety and effectiveness of emerging therapies.

This review highlights that androgenetic alopecia significantly impacts psychological well-being and quality of life, emphasizing the need for integrated psychological support alongside dermatological treatment.

This systemic review and meta-analysis found that men with androgenetic alopecia generally experience moderate impacts on quality of life, but limited evidence of severe effects on mental health.

This study reviewed existing literature and found that green tea may have potential as a treatment for male androgenetic alopecia, demonstrating hair growth stimulation and fewer adverse reactions compared to minoxidil, despite being used in smaller concentrations.

This review discusses the diagnostic features of androgenetic alopecia through trichoscopy and reports no clinical results; it emphasizes hair shaft variability and yellow dots as key indicators.

Masculinizing hormone therapy increases the risk of hair loss in transgender and gender-diverse patients.

In this study, researchers developed a probiotic-based microneedle system combining Weissella cibaria and clascoterone to target androgenetic alopecia, which in a mouse model improved hair density, vascular regeneration, and reduced inflammation, suggesting a promising treatment approach.